Senti Biosciences Holdings, Inc. (SNTI) stock
Close on Nov 11, 2026Market cap $4.90MP/E –Yield –
Senti Biosciences Holdings, Inc. reported revenue of $22.00K for fiscal 2025. Free cash flow was -$43.64M. At the latest close the market valued the company at $4.90M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $4.90M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $22.00K
- Net income
- -$49.56M
- EPS, diluted
- -$1.77
- Free cash flow
- -$43.64M
- Book value per share
- -$0.11
- Diluted shares
- 31M
Trading
- Next earnings
- Nov 12, 2026 (estimated, after the close)
- Previous close
- $0.14
- Open
- $0.14
- Day's range
- $0.14 – $0.16
- Volume
- 225,286
- Average volume (20 days)
- 9,928,320
- Beta (5 years)
- 1.86
- 52-week range
- $0.14 – $2.88
- RSI (14 days)
- 34.9
- Volatility (1 year)
- 106.1%
- Relative volume
- 0.09×
- WACC
- 14.2%
Market cap history
Month-end market cap since 2022, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | SNTI | S&P 500 | Difference | SNTI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -50.0% | -2.4% | −47.6 pts | ||
| 3 months | -56.0% | -1.2% | −54.9 pts | ||
| Year to date | -84.9% | +12.3% | −97.2 pts | ||
| 1 year | -91.4% | +12.4% | −103.9 pts | ||
| 3 years | -97.0% | +78.8% | −175.8 pts | -68.8% | +21.4% |
| 5 years | -99.8% | +75.2% | −175.0 pts | -72.5% | +11.9% |
Six years at a glance
Fiscal years 2020 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Senti Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Update
About Senti Biosciences
Biological Products, (No Diagnostic Substances)
Senti Biosciences is a clinical-stage biotechnology company that develops cell and gene therapies using synthetic biology and proprietary gene circuit technologies. The company programs cells with biological logic to target and destroy cancer cells while sparing healthy tissue. Its lead product candidate is SENTI-202, an off-the-shelf chimeric antigen receptor natural killer cell therapy designed to treat relapsed or refractory hematological malignancies, including acute myeloid leukemia. In addition to internal oncology initiatives, Senti Biosciences maintains preclinical programs in solid tumors and partners with BlueRock Therapeutics to develop cell therapies for regenerative medicines.
Company profile, executives and historySenti Biosciences stock: common questions
What is Senti Biosciences's stock price?
SNTI closed at $0.16 on Nov 11, 2026, up 11.81% on the day. Over the past 52 weeks it traded between $0.14 and $2.88.
What is Senti Biosciences's market cap?
Senti Biosciences was worth $4.90M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is SNTI's P/E ratio?
Senti Biosciences lost money over the twelve months to Jun 30, 2026 (diluted EPS -$1.77), so it has no meaningful P/E ratio.
How much revenue does Senti Biosciences make?
Senti Biosciences reported revenue of $22.00K for fiscal 2025.
Does Senti Biosciences pay a dividend?
No. Senti Biosciences has not paid a cash dividend over the last twelve months.
When does Senti Biosciences report earnings next?
Senti Biosciences is expected to report Q3 FY2026 results on Nov 12, 2026, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has SNTI stock performed over the past year?
Including dividends, SNTI returned -91.4% over the past year, against +12.4% for the S&P 500.
Who are Senti Biosciences's competitors?
Companies most similar to Senti Biosciences by business, industry and size include ALLO, LYEL, INMB, KZIA, GNLX.
See a number that looks wrong?